Neway has announced a strategic lab services arrangement with Quest Diagnostics to speed up dialysis laboratory testing and lower dialysis programme laboratory costs for end-stage renal disease (ESRD) patients.

As per the agreement terms, Neway will access Quest’s lab network to deliver local dialysis laboratory testing services with next-day results after arrival.

Quest's distributed lab network will allow Neway and its affiliated dialysis centres to quickly complete testing and deliver results with reduced transportation costs.

The partnership will offer an alternative to the centralised lab model under which specimens from several dialysis programmes in the US are transported to a single laboratory for processing.

Neway founder and CEO Bryan Thompson said: “The old model of generally relying on air transportation of dialysis laboratory specimens to a single US location is costly and can take days for results.

“The 'new way' for dialysis laboratory testing is a decentralised network of laboratory locations that spans the nation. This approach is good for dialysis patients, dialysis programmes, insurance payers and the entire dialysis industry.”

Available through Quest’s subspecialty pathology business AmeriPath, the tissue-based test service helps meet the critical clinical requirement for detecting and distinguishing potentially aggressive prostate cancer cases in men.

In July of this year, Quest and Envision Sciences announced a partnership to launch a new prostate cancer biomarker test.